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Aim. Atypical presentations of celiac disease (CD) have now been shown to be much more common than classical (typical) form.
We evaluated the frequency of CD among adult patients with typical or atypical symptoms of CD. Materials and Methods. Patients
referredtotwooutpatientgastroenterologyclinicsinIsfahan(IRAN)werecategorizedintothosewithtypicaloratypicalsymptoms
of CD. IgA antitissue transglutaminase antibody was assessed and followed by duodenal biopsy. In patients for whom endoscopy
was indicated (independent of the serology), duodenal biopsy was taken. Histopathological changes were assessed according to the
Marsh classiﬁcation. Results. During the study period, 151 and 173 patients with typical and atypical symptoms were evaluated
(mean age = 32.8 ± 12.6a n d3 5 .8 ± 14.8 years, 47.0% and 56.0% female, resp.). Frequency of CD in patients with typical and
atypical symptoms was calculated, respectively, as 5.9% (9/151) and 1.25% (3/173) based on positive serology and pathology.
The overall frequency was estimated as at least 9.2% (14/151) and 4.0% (7/173) when data of seronegative patients were also
considered. Conclusions. CD is more frequent among patients with typical symptoms of malabsorption and these patients should
undergo duodenal biopsy, irrespective of the serology. In patients with atypical symptoms, serological tests should be performed
followed by endoscopic biopsy, and routine duodenal biopsy is recommended when endoscopic evaluation is indicated because of
symptoms.
1.Introduction
Celiac Disease (CD), also known as gluten-sensitive enter-
opathy, is a genetic disorder aﬀecting both children and
adults. People with CD are unable to eat foods that
contain gluten because, in these patients, gluten sets oﬀ
an autoimmune reactions that cause the destruction of
the small intestinal villi and leading to a malabsorption
syndrome [1, 2]. While it was previously thought to be
rare, epidemiological studies using sensitive and speciﬁc
serological tests with biopsy veriﬁcation established higher
prevalence of CD (up to 1:100) in most countries [3–5].
Classical symptoms of CD in adults include chronic diar-
rhea, steatorrhea, and weight loss. Steatorrhea is associated
with severe, extensive enteropathy, but it is often absent
in patients whose disease is limited to the more proximal
portions of the small intestine [2]. Classical symptoms of CD
are present in less than 50% of the patients at presentation
[1]. Abdominal discomfort and bloating are common at
early presentation and often result in a mistaken diagnosis
of more common gastrointestinal disorders such as irritable
bowel syndrome (IBS) and dyspepsia for a long time, which
contributes to a considerable delay in diagnosing CD [6, 7].
Untreated CD can be life threatening and increase the risk
of certain types of cancer and lymphoma and also increase
the risk of mortality compared to the general population [8].
Although there are no drugs to treat CD and there is no cure,
agluten-freediet(GFD)canleadtoanormalandhealthylive2 Gastroenterology Research and Practice
and can decrease the risk of malignancy and mortality [2, 8].
Therefore, prompt diagnosis of the disease and nutritional
treatment is of great value.
Despite the large epidemiological studies and screening
and nutritional programs conducted in western countries,
there are only a few investigations on the prevalence of CD
in the general population in Asia, particularly Middle East
[5, 9]. Epidemiological studies in Iran also are insuﬃcient
to provide an accurate estimation of CD among high risk or
suspicious groups. Since there are few documented cases of
CD in our society, it seems to be remained underdiagnosed
[5].
There is still a controversy on cost-eﬀectiveness and
beneﬁts of the population screening for CD [10, 11]. In
the absence of a population screening program, targeting
the screening to the certain high risk groups (case ﬁnding
approach) can be an eﬃcient use of the resources [10].
Epidemiological studies providing an estimated prevalence
among diﬀerent target groups (e.g., apparently healthy, sus-
picious CD, and high-risk groups) will enable us to establish
further genetic, immunologic, and nutritional researches
to control the disease. According to the wide aspects of
presentationandvarietyofcomplications,andalsoregarding
the lack of epidemiologic data on CD in Iran, we aimed
to determine the prevalence of CD among patients referred
with typical or atypical symptoms of malabsorption to see if
routine screening of these patients is worthwhile.
2.MaterialsandMethods
2.1. Patients and Setting. This study was conducted between
2004 and 2005, on all patients with typical or atypical
symptoms of CD referred to Poursina Hakim Research Insti-
tute (including two outpatient clinics of gastroenterology)
in Isfahan, Iran. Classic or typical symptoms of CD were
considered as chronic diarrhea, steatorrhea, and weigh loss.
Atypical symptoms included unexplained abdominal pain,
excessive gas passing, malodor stool or gas, constipation,
intermittent diarrhea, bloating, and unexplained nausea or
vomiting. The ethics committee of the Isfahan University of
Medical Sciences approved the study and informed consent
was obtained from all patients after explaining the aims and
protocol.
2.2. Assessments. Data including demographics, clinical
symptoms, complete past medical history, and associated
disorders, and family history of CD were collected by a
trained physician using a structured questionnaire. Labo-
ratory data included thyroid function test, complete blood
c o u n t( C B C ) ,E S R ,C R P ,c a l c i u m ,p h o s p h o r ,a n d3t i m e s
stool examination for all patients.
2.3. Serological Assessment for CD. The IgA antitissue transg-
lutaminase(anti-tTG)antibodywasmeasuredforallpatients
using an enzyme-linked immunosorbant assay (ELIZA)
technique by a commercially available kit (ORG540 A,
ORGENTEC Diagnostica GmbH). The upper limit of the
normal range (cut-oﬀ value) for t-TG IgA antibody, as
determined by the manufacturer, was 10u/mL. If the results
was very low (<5Au/mL), IgA level was measured to rule out
IgA deﬁciency.
2.4. Pathological Assessment for CD. Endoscopic biopsy
was recommended to all patients with typical symptoms,
seropositive atypical cases, and those with IgA deﬁciency [1,
12]. Also, duodenal biopsy was done in seronegative patients
with atypical symptoms, who had other indications of
upper gastrointestinal endoscopy (due to their symptoms).
Endoscopy was done with a standard 110cm long video
endoscope (EG 2940, Pentax EPM-3300), by a single gas-
troenterologist, during which at least four biopsy specimens
were obtained from the distal part of the second portion of
duodenum. The specimens were processed and stained with
hematoxylin and eosin and studied under light microscopy
by a gastrointestinal oriented pathologist. Histopathology
was reported according to the modiﬁed Marsh classiﬁcation
[13]; Marsh type I: inﬁltrative phase with >30 lymphocytes
per 100 enterocytes; Marsh II: inﬁltrative/hyperplastic phase;
Marsh IIIA, IIIB, and IIIC: partial, subtotal, and total
villous atrophy, respectively. Seropositive patients with at
least Marsh I of villous atrophy and also seronegative cases
with Marsh II or III of villous atrophy were considered to
have CD if they had good response to GFD [12].
2.5. Statistical Analysis. The data were analyzed using SPSS
software for Windows v 16.0 (SPSS Inc., Chicago, IL, USA).
Comparisons were done with independent t-test or Mann-
Whitney test for quantitative and Chi-square or Fisher’s
exact tests for qualitative data, and a P value of <0.05 was
considered to be signiﬁcant.
3. Results
During the study period, 151 patients with typical symptoms
(mean age = 32.8 ± 12.6, 47.0% female) and 173 patients
with atypical symptoms (mean age = 35.8 ± 14.8, 56.0%
female) were evaluated. Comparisons of the two groups
regarding demographic characteristics and symptoms are
presented in Table 1.T h ed i ﬀerences between patients with
typical and atypical symptoms in age and gender were
not statistically signiﬁcant (P>0.05). The frequency of
intermittentdiarrheaandconstipationwashigherinatypical
(P<0.05) and fatigue/weakness in typical cases (P<0.001).
Duration of symptoms was longer in patients with atypical
symptoms (P<0.05).
3.1. Patients with Typical Symptoms for CD. In patients with
typical symptoms, thyroid function test, stool exam, ESR
and CBC results did not specify a diagnosis. Patients ≥ 50
yearsold(17cases)underwenttotalcolonoscopyandnoneof
themhadmalignancyorinﬂammatoryboweldisease.Family
history of CD was not reported and IgA deﬁciency was not
detected in any patient. Totally, 8.6% (13/151) of the patients
with typical symptoms were seropositive for tTG-IgA, 12
patients accepted to undergo endoscopy. Histopathological
studies showed Marsh IIIc in 4, Marsh IIIb in 3, andGastroenterology Research and Practice 3
Table 1: Patients’ characteristics.
Typical Atypical P
N = 151 N = 173
Age (year) 32.8 ±12.63 5 .8 ±14.8 0.057∗
Male/Female 80 (52.9%)/71 (47.0%) 76 (43.9%)/97 (56.0%) 0.065∗∗
Symptoms
Chronic Diarrhea 107 (70.8%) — —
Steatorrhea 40 (26.4%) — —
Weight Loss 64 (42.3%) — —
Abdominal Pain 80 (52.9%) 79 (45.6%) 0.115∗∗
Bloating 68 (45.0%) 75 (43.3%) 0.424∗∗
Intermittent Diarrhea 8 (5.2%) 26 (15.0%) 0.005∗∗
Constipation 30 (19.8%) 60 (34.6%) 0.002∗∗
Flatulence 65 (43.0%) 88 (51.4%) 0.098∗∗
Fatigue/Weakness 56 (37.0%) 30 (17.3%) <0.001∗∗
Symptom Duration (Month) 36.3 (SE = 3.6) 54.7 (SE = 5.7) 0.008∗
Data are presented as mean ± SD (SE) or number (%).
∗Independent Sample t-Test or Mann-Whitney Test.
∗∗Chi-Square or Fisher’s Exact Tests.
Marsh I in 2 patients. As upper gastrointestinal endoscopy
was oﬀered to all patients, 40.2% (56/139) accepted this
procedure. Histopathological studies among these patients
showed Marsh IIIc in 1, Marsh IIIb in 2, Marsh IIIa in
3, Marsh II in 1, and Marsh I in 9 patients. GFD was
started in all patients with positive serology and a biopsy
result suggestive of CD and in seronegative patients with
Marsh III or II. One seronegative patient with Marsh IIIc
and one with Marsh II did not respond to GFD and after
more evaluation including colonoscopy, the patient with
Marsh IIIc was diagnosed to have Crohn’ disease. Other
patients responded to GFD clinically and antibody became
negative after six months in seropositive cases. Therefore,
the prevalence of CD in patients with typical symptoms
was calculated as 5.9% (9/151) based on positive serology
and conﬁrmed pathology and the overall prevalence was
estimated asatleast 9.2% (14/151) whendata of seronegative
patients were considered, as well. Patients’ characteristics are
shown in Table 2.
3.2. Patients with Atypical Symptoms for CD. In this group,
8 patients were diagnosed to have IgA deﬁciency, but none
of them had CD. Totally, 2.8% (5/173) of the patients were
seropositive for IgA anti-tTG, and in all of them duodenal
biopsy was taken. Marsh II was shown in 3 of the patients,
and 2 of them had normal histopathologic examination. As
upper gastrointestinal endoscopy was oﬀered to all patients
with prolonged and unexplained symptoms, 37.5% (63/168)
patients accepted this procedure. Among these patients, 2
had Marsh IIIa, 2 had Marsh II, and 6 Marsh I. GFD was
started in all patients with positive serology and a biopsy
result suggestive of CD and also in seronegative patients with
Marsh III or II. All patients responded to GFD clinically
and serology became negative in seropositive cases after
six months. Finally, the prevalence of CD in patients with
Table 2: Patients with CD and typical/atypical symptoms.
Typical Atypical P
N = 14 N = 7
Age, year 33.5 ±13.03 9 .2 ±12.3 0.795∗
Male/Female 6 (42.8%)/8
(57.1%)
3 (42.8%)/4
(57.1%) 0.676∗∗
Positive serology 9 (64.2%) 3 (42.8%) 0.319∗∗
Marsh classiﬁcation
I 2 (14.2%) 0
0.004∗∗
II 0 5 (71.4%)
IIIA 3 (21.4%) 2 (28.5%)
IIIB 5 (35.7%) 0
IIIC 4 (28.5%) 0
Data are presented as mean ± SD (SE) or number (%).
∗Independent Sample t-test or Mann-Whitney test.
∗∗Chi-Square or Fisher’s Exact Tests.
atypical symptoms was calculated as 1.25% (3/173) based
on positive serology conﬁrmed by pathology and the overall
prevalence was estimated at least 4.0% (7/173) when data
of seronegative patients were considered, as well. Patients’
characteristics are shown in Table 2. The frequency of CD
was higher in typical than in atypical patients (OR = 2.423,
CI 95% = 0.95 to 6.17, P = 0.046 (one sided)).
Comparing patients with and without CD regarding
presenting symptoms is presented in Table 3. Abdominal
pain, diarrhea, bloating, and steatorrhea were more frequent
in CD than non-CD patients (P<0.05), but the diﬀerences
regarding other symptoms were not statistically signiﬁcant.
Also, there was no signiﬁcant diﬀerence between CD and
non-CD cases in age or gender (P>0.05).4 Gastroenterology Research and Practice
Table 3: Comparison of symptoms between patients with and without CD.
CD Non-CD P
N = 21 N = 303
Age (year) 32.8 ±12.63 5 .8 ±14.8 0.057∗
Male/Female 9 (42.8%)/12 (57.1%) 147 (48.5%)/156 (51.4%) 0.065∗∗
Abdominal Pain 15 (71.4%) 144 (47.5%) 0.028∗∗
Diarrhea 13 (61.9%) 120 (39.6%) 0.039∗∗
Bloating 15 (71.4%) 128 (42.2%) 0.009∗∗
Constipation 3 (14.2%) 87 (28.7%) 0.117∗∗
Weight Loss 5 (23.8%) 59 (19.4%) 0.402∗∗
Flatulence 9 (42.8%) 144 (47.5%) 0.427∗∗
Fatigue/Weakness 9 (42.8%) 77 (25.4%) 0.072∗∗
Steatorrhea 6 (28.5%) 34 (11.2%) 0.032∗∗
Data are presented as mean ± SD (SE) or number (%).
∗Independent Sample t-test or Mann-Whitney test.
∗∗Chi-Square or Fisher’s Exact Tests.
4. Discussion
Previously, CD has been considered to be very rare in the
Middle East and, based on this assumption, it was not gener-
ally considered as a possibility in the diﬀerential diagnosis of
patients coming with nonspeciﬁc gastrointestinal symptoms
[9]. By the development of more sensitive serological tests
and a higher degree of disease suspicion, a marked increase
in CD prevalence and incidence has been reported in recent
decade [5]. Some evidence showed that a large proportion
of patients present with atypical symptoms of malabsorption
that can lead to misdiagnosis for a prolonged time [6, 14].
This delay can result in higher complications of CD such as
diﬀerent types of cancer and organ damage. Thus, prompt
diagnosis of CD is of great important and while there is
still a controversy on the cost-eﬀectiveness of population
screening for CD, case ﬁnding approach is more ﬁnancially
viable [10]. With this approach, we attempted to determine
the frequency of CD in patients presenting with typical
symptoms of malabsorption and those with nonspeciﬁc
gastrointestinal complaints. We found that CD is present in
about 9.2% of the patients coming with typical symptoms
(12.1% (13/107) of the patients with chronic diarrhea)
and 4.0% of those who come with atypical symptoms
of malabsorption. Other studies from Iran also reported
that CD is the most common cause of chronic nonbloody
diarrhea in adults and children, ranging from 6.5% to 19%
[15, 16]. These results indicate that classic presentation
of malabsorption, specially with chronic diarrhea, is the
main presentation of CD in our society. However, we found
that 4.0% of patients coming to the outpatient clinics of
gastroenterology with nonspeciﬁc symptoms of CD ﬁnally
were diagnosed to have CD, which is much higher than that
reported from screening studies of the general population in
I r a n ,u pt o1 %[ 5]. Dyspepsia and IBS are the most common
disordersdiagnosedinoutpatientclinics ofgastroenterology.
There are some studies with case ﬁnding approach that are
done in these patients. The frequency of CD is reported from
1.4% [17]t o7 %[ 18] in people with dyspeptic complaints
and from 0.4% to 11.4% in patients with IBS [19–21]. A
meta-analysis showed that biopsy-conﬁrmed CD is 4-fold
more prevalent in IBS patients than the general population
(Pooled odds ratio = 4.34, CI 95% = 1.78–10.6) [22]. Studies
with cost-eﬀective analyses showed that testing for CD in
patients with IBS-like symptoms is acceptable when the
prevalence of CD is above 1% and it is a dominant strategy
when the prevalence exceeds 8% and also in those with
diarrhea predominant IBS [23, 24]. In spite of this evidence,
most of the studies from Iran have shown no diﬀerence
between patients with IBS-like symptoms and the general
population in the frequency of CD [25]. More recent studies
with large sample sizes also did not ﬁnd a higher frequency
of CD [20] even among patients with diarrhea-predominant
IBS [19]. Therefore, decision for screening of these patients
must be based on the population prevalence of CD, the
accuracy of serological tests in that population, and the costs
of IBS treatment [23].
An important ﬁnding in our study was the low sensitivity
of serology (anti-tTG IgA antibody) in detecting CD patients
specially in patients presenting with atypical symptoms. IgA
anti-tTG antibody is the single most eﬃcient serological
test for the diagnosis of CD [26, 27]. It is well known that
IgA anti-tTG levels correlate with the degree of intestinal
damage, and that values can ﬂuctuate in patients over time
[28, 29]. Serological tests help in diagnosis of CD, but the
gold standard is based on pathological study. We found
that about 35% of CD patients with typical symptoms are
seronegative that shows the best method for diagnosing CD
in these patients is a panel of serological tests and endoscopic
biopsy together, which is previously recommended by other
investigators [1]. In patients with non-speciﬁc gastrointesti-
nal symptoms we found positive serology in less than half
of the patients. Accordingly we recommend that diagnostic
approach in such patients should be started with serological
tests and when the endoscopy is indicated for evaluation
of the symptoms, duodenal biopsy and evaluation for CD
histopathology should be considered. During the endoscopy,
the presence of features of villous atrophy (such as scallopingGastroenterology Research and Practice 5
of mucosal folds, absent or reduced duodenal folds, or a
mosaic pattern of the mucosa) has a high negative predictive
value for CD and could be helpful in decision for biopsy
[30, 31]. However, such features have a very low sensitivity
[31, 32] and also evidence has shown that duodenal biopsies
reveal other abnormalities and could be helpful in patients
with chronic diarrhea and/or abdominal pain for further
following workups [33]. Therefore, we recommend routine
duodenal biopsy in endoscopic evaluation of patients refer-
ring with nonspeciﬁc gastrointestinal symptoms.
5. Conclusion
W ef o u n dt h a tC Di sm o r ep r e v a l e n ta m o n gp a t i e n t s
referring with typical symptoms of malabsorption specially
chronic diarrhea than patients with atypical symptoms.
Any patient who has classic symptoms of CD should
undergo duodenal biopsy, irrespective of whether serologic
testing for CD has been performed or was positive. In
patients with atypical symptoms, serological tests should be
performed followed by endoscopic biopsy. In these patients,
routine duodenal biopsy is recommended when endoscopic
evaluation is indicated.
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